Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 71320-77-9 Chemical Structure| 71320-77-9

Structure of Moclobemide
CAS No.: 71320-77-9

Chemical Structure| 71320-77-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Moclobemide is a reversible MAO-A inhibitor.

Synonyms: Ro111163

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Moclobemide

CAS No. :71320-77-9
Formula : C13H17ClN2O2
M.W : 268.74
SMILES Code : O=C(NCCN1CCOCC1)C2=CC=C(Cl)C=C2
Synonyms :
Ro111163
MDL No. :MFCD00865388
InChI Key :YHXISWVBGDMDLQ-UHFFFAOYSA-N
Pubchem ID :4235

Safety of Moclobemide

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H315-H318-H335
Precautionary Statements:P261-P280-P305+P351+P338
Class:8
UN#:1759
Packing Group:

Isoform Comparison

Biological Activity

Target
  • MAO-A

    MAO-A (5-HT), IC50:6.1 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat hippocampal neural stem cells 200 μM Cells did not survive PMC1751867
Rat hippocampal neural stem cells 50 μM Promoted differentiation of neural stem cells into serotoninergic neuron-like cells, increased cell survival, upregulated expression of antiapoptotic genes Bcl-2 and Bcl-XL PMC1751867
Neural stem cells (NSCs) 50 μM 24, 48, 72 hours Moclobemide increases the viability and proliferation of NSCs, upregulates the gene expressions of Bcl-2 and Bcl-xL, and prevents FasL-induced apoptosis PMC1751873

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Albino Swiss mice Forced swim test (FST) and tail suspension test (TST) Intraperitoneal injection 1.5 mg/kg Single dose, 60 min before To evaluate the impact of CB receptor ligands on the antidepressant activity of Moclobemide. Results showed that AM251 (0.25 mg/kg) potentiated the antidepressant effects of Moclobemide. PMC7704509
Swiss Albino mice Tail suspension test and forced swimming test Intraperitoneal injection 30 mg/kg Three doses within 24 hours (t = 0, 18, 24 hours) Evaluation of antidepressant activity, results showed Moclobemide as a standard drug exhibited antidepressant potential at 30 mg/kg dose PMC8818363
Mice Acute pain model Intraperitoneal injection 69.1 mg/kg Single administration To evaluate the antinociceptive effect of Moclobemide in a mouse model of acute pain and its interaction with the opioid system. Results showed that Moclobemide produced a dose-dependent antinociceptive effect, but this effect was not significantly inhibited by naloxone, indicating no opioid involvement in its antinociceptive effect. PMC10342252

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02269540 Major Depressive Disorder Early Phase 1 Recruiting July 2018 Canada, Ontario ... More >> Research Imaging Centre, Centre for Addiction and Mental Health Recruiting Toronto, Ontario, Canada, M5T 1R8 Principal Investigator: Jeffrey H Meyer, MD, PhD Less <<
NCT01544309 Hypercholesterolemia With Conc... More >>omitant Type 2 Diabetes Less << Not Applicable Completed - -
NCT00068224 - Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01544309 - Completed - -
NCT01962753 Elderly Major... More >> Depression Less << Not Applicable Unknown May 2018 France ... More >> University Hospital of Besançon- Jean Minjoz Recruiting Besançon, France, 25030 Contact: Pierre VANDEL       pierre.vandel@univ-fcomte.fr    University Hospital of Caen Recruiting Caen, France, 14000 Contact: Sonia DOLLFUS       dollfus-s@chu-caen.fr    University Hospital of Lille Recruiting Lille, France, 59000 Contact: Jean ROCHE       Jean.ROCHE@CHRU-LILLE.FR    University Hospital of Nice Recruiting Nice, France, 06000 Contact: Philippe ROBERT       robert.p@chu-nice.fr    Sainte-Anne Hospital Recruiting Paris, France, 75014 Contact: Thierry GALLARDA       T.GALLARDA@ch-sainte-anne.fr    Le Rouvray Hospital Recruiting Sotteville lès Rouen, France, 76300 Contact: Marie DESBORDES       marie.desbordes@ch-lerouvray.fr    University Hospital of Strasbourg - HUS Recruiting Strasbourg, France, 67098 Contact: Frédéric BLANC       frederic.blanc@chru-strasbourg.fr    University Hospital of Toulouse - Purpan Recruiting Toulouse, France, 31059 Contact: Christophe ARBUS       arbus.c@chu-toulouse.fr    University Hospital of Tours Recruiting Tours, France, 37000 Contact: Vincent CAMUS       vincent.camus@univ-tours.fr Less <<
NCT00704860 Major Depression Phase 4 Completed - Canada, Ontario ... More >> University of Ottawa Institute of Mental Health Research Ottawa, Ontario, Canada, K1Z 7K4 Less <<
NCT02222220 Clozapine-induced Hypersalivat... More >>ion Less << Phase 3 Completed - Israel ... More >> Be'er Sheva Mental Health Center, Be'er Sheva, Israel, 8417000 Less <<
NCT03010761 Addiction Phase 2 Terminated(all participants fi... More >>nished the trial) Less << - -
NCT00534573 Clozapine-induced Hypersalivat... More >>ion Less << Phase 3 Completed - Israel ... More >> Be'er Sheva Mental Health Center, Tirat HaKarmel Mental Health Center Be'er Sheva, Haifa, Israel Less <<
NCT01926626 Nicotine Dependence Phase 2 Completed - United States, North Carolina ... More >> Duke Center for Smoking Cessation Charlotte, North Carolina, United States, 28210 Duke Center forSmoking Cessation Durham, North Carolina, United States, 27705 Duke Center for Smoking Cessation Winston-Salem, North Carolina, United States, 27103 Less <<
NCT01926626 - Completed - -
NCT02374567 Dementia Depr... More >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders Less << Phase 3 Terminated - Germany ... More >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.72mL

0.74mL

0.37mL

18.61mL

3.72mL

1.86mL

37.21mL

7.44mL

3.72mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories